Want to see OKYO full AI Analyst Report?
OKYO Stock Chart & Stats
$1.66
$0.09(7.75%)
At close: 4:00 PM EST
$1.66
$0.09(7.75%)
Day’s Range― - ―
52-Week Range$1.42 - $3.35
Previous CloseN/A
Volume700.83K
Average Volume (3M)131.52K
Market Cap
$86.30M
Enterprise Value$56.20M
Total Cash (Recent Filing)$4.22M
Total Debt (Recent Filing)$185.79K
Price to Earnings (P/E)―
Beta0.51
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding51,370,197
10 Day Avg. Volume47,624
30 Day Avg. Volume131,524
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-9.04
Price to Sales (P/S)0.00
P/FCF Ratio-27.67
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-25.85K
Enterprise Value/Ebitda-5.86
Forecast
1Y Price Target
$7.00Price Target Upside321.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development Progress And Market PotentialA planned 120-patient Phase 2b/3 multiple-dose trial, combined with no currently approved therapies for this condition and a differentiated mechanism, creates a clear clinical catalyst and sizable commercial opportunity if efficacy is confirmed.
Clinical Efficacy And SafetyPhase 2 results demonstrated meaningful pain reduction with urcosimod while maintaining a clean safety profile, supporting potential clinical benefit for patients with neuropathic corneal pain.
Regulatory AlignmentFDA endorsement of the pain scale as a clinically meaningful endpoint, together with agreement on study design, sample size and statistical guidance, increases the chance of a robust pivotal trial and clearer regulatory pathway.
Bears Say
Limited Data On Corneal Nerve FindingsCorneal image improvements are derived from a small exploratory analysis and require confirmation in larger trials, leaving the nerve restoration signal uncertain.
Program Risk ProfileThe program faces risks across clinical, regulatory, commercial, financing and intellectual property areas, any of which could delay development or limit future market access.
OKYO Pharma Limited Sponsored ADR News
OKYO FAQ
What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?
OKYO Pharma Limited Sponsored ADR lowest stock price was $1.42 and its highest was $3.35 in the past 12 months.
What is OKYO Pharma Limited Sponsored ADR’s market cap?
OKYO Pharma Limited Sponsored ADR’s market cap is $86.30M.
When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?
Currently, no data Available
Is OKYO Pharma Limited Sponsored ADR overvalued?
According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued.
Does OKYO Pharma Limited Sponsored ADR pay dividends?
OKYO Pharma Limited Sponsored ADR does not currently pay dividends.
What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?
OKYO Pharma Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?
OKYO Pharma Limited Sponsored ADR has 51,370,197 shares outstanding.
What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?
Currently, no hedge funds are holding shares in OKYO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OKYO Pharma Limited Sponsored ADR Stock Smart Score
Company Description
OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
OKYO Stock 12 Month Forecast
Average Price Target
$7.00
▲(321.69% Upside)
Technical Analysis
Ownership Overview
21.11% Insiders
0.02% Mutual Funds
11.06% Other Institutional Investors
67.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---